168 related articles for article (PubMed ID: 18027241)
1. Addressing liver fibrosis with liposomes targeted to hepatic stellate cells.
Adrian JE; Poelstra K; Kamps JA
J Liposome Res; 2007; 17(3-4):205-18. PubMed ID: 18027241
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats.
Adrian JE; Poelstra K; Scherphof GL; Meijer DK; van Loenen-Weemaes AM; Reker-Smit C; Morselt HW; Zwiers P; Kamps JA
J Pharmacol Exp Ther; 2007 May; 321(2):536-43. PubMed ID: 17314198
[TBL] [Abstract][Full Text] [Related]
3. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis.
Bansal R; Prakash J; de Ruijter M; Beljaars L; Poelstra K
Mol Pharm; 2011 Oct; 8(5):1899-909. PubMed ID: 21800888
[TBL] [Abstract][Full Text] [Related]
4. A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats.
Adrian JE; Kamps JA; Scherphof GL; Meijer DK; van Loenen-Weemaes AM; Reker-Smit C; Terpstra P; Poelstra K
Biochim Biophys Acta; 2007 Jun; 1768(6):1430-9. PubMed ID: 17493581
[TBL] [Abstract][Full Text] [Related]
5. Disease-induced drug targeting using novel peptide-ligand albumins.
Meijer DK; Beljaars L; Molema G; Poelstra K
J Control Release; 2001 May; 72(1-3):157-64. PubMed ID: 11389994
[TBL] [Abstract][Full Text] [Related]
6. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis.
El-Mezayen NS; El-Hadidy WF; El-Refaie WM; Shalaby TI; Khattab MM; El-Khatib AS
J Control Release; 2017 Nov; 266():226-237. PubMed ID: 28965860
[TBL] [Abstract][Full Text] [Related]
7. Cooperation of liver cells in health and disease.
Kmieć Z
Adv Anat Embryol Cell Biol; 2001; 161():III-XIII, 1-151. PubMed ID: 11729749
[TBL] [Abstract][Full Text] [Related]
8. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells.
Beljaars L; Molema G; Weert B; Bonnema H; Olinga P; Groothuis GM; Meijer DK; Poelstra K
Hepatology; 1999 May; 29(5):1486-93. PubMed ID: 10216133
[TBL] [Abstract][Full Text] [Related]
9. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Losartan-Loaded Hyaluronic Acid (HA) Micelles for the Reduction of Advanced Hepatic Fibrosis in C3H/HeN Mice Model.
Thomas RG; Moon MJ; Kim JH; Lee JH; Jeong YY
PLoS One; 2015; 10(12):e0145512. PubMed ID: 26714035
[TBL] [Abstract][Full Text] [Related]
11. The improving effects on hepatic fibrosis of interferon-γ liposomes targeted to hepatic stellate cells.
Li Q; Yan Z; Li F; Lu W; Wang J; Guo C
Nanotechnology; 2012 Jul; 23(26):265101. PubMed ID: 22700686
[TBL] [Abstract][Full Text] [Related]
12. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis.
Beljaars L; Meijer DK; Poelstra K
Front Biosci; 2002 May; 7():e214-22. PubMed ID: 11991830
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 knockdown attenuates the ameliorative effects of ligustrazine on hepatic fibrosis by targeting hepatic stellate cell transdifferentiation.
Lu C; Xu W; Zhang F; Shao J; Zheng S
Toxicology; 2016 Jul; 365():35-47. PubMed ID: 27477297
[TBL] [Abstract][Full Text] [Related]
14. [Hepatic fibrogenesis].
Lee KS
Korean J Gastroenterol; 2006 Nov; 48(5):297-305. PubMed ID: 17132917
[TBL] [Abstract][Full Text] [Related]
15. Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomes.
Adrian JE; Kamps JA; Poelstra K; Scherphof GL; Meijer DK; Kaneda Y
J Drug Target; 2007 Jan; 15(1):75-82. PubMed ID: 17365276
[TBL] [Abstract][Full Text] [Related]
16. Prevention of rat liver fibrosis by selective targeting of hepatic stellate cells using hesperidin carriers.
Morsy MA; Nair AB
Int J Pharm; 2018 Dec; 552(1-2):241-250. PubMed ID: 30291958
[TBL] [Abstract][Full Text] [Related]
17. New Developments on the Treatment of Liver Fibrosis.
Koyama Y; Xu J; Liu X; Brenner DA
Dig Dis; 2016; 34(5):589-96. PubMed ID: 27332862
[TBL] [Abstract][Full Text] [Related]
18. Liver fibrosis: Direct antifibrotic agents and targeted therapies.
Schuppan D; Ashfaq-Khan M; Yang AT; Kim YO
Matrix Biol; 2018 Aug; 68-69():435-451. PubMed ID: 29656147
[TBL] [Abstract][Full Text] [Related]
19. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy.
Li D; Friedman SL
J Gastroenterol Hepatol; 1999 Jul; 14(7):618-33. PubMed ID: 10440206
[TBL] [Abstract][Full Text] [Related]
20. Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats.
Li F; Li QH; Wang JY; Zhan CY; Xie C; Lu WY
J Control Release; 2012 Apr; 159(2):261-70. PubMed ID: 22226772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
